Lv12
62 积分 2025-03-04 加入
Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE
22小时前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
6天前
已完结
Targeting HER2 in urothelial carcinoma: from pathway inhibition to antibody-drug conjugates
1个月前
已完结
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
6个月前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
6个月前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
6个月前
已完结
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
7个月前
已完结
Antibody-drug conjugates in urothelial carcinoma: current status and future
7个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
7个月前
已完结
皖公网安备34019202002308
